DNA Topoisomerase II: Promising Target for Anticancer Drugs

作者: Paramjeet Kaur , Varinder Kaur , Satwinderjeet Kaur

DOI: 10.1007/978-3-319-12253-3_20

关键词: CancerChemistryToxinCancer cellTopoisomerase inhibitorEnzymeBiochemistryTopoisomerase-II InhibitorProgrammed cell deathTopoisomerase

摘要: Topoisomerase II inhibitors are being researched as targets for the generation of antineoplastic drugs because inhibition topoisomerase by theses leads to cell death. Inhibitors bind with molecule thus making enzyme nonfunctional and converting it into a cellular toxin that fragments genome. Cancer cells divide more rapidly than normal cells. Thus, cancer would be killed preferably instead inhibitors. The which decrease overall activity this called catalytic increase level topoisomerase–DNA-cleaved complexes poisons. poisons further divided intercalating non-intercalating. Phytochemicals have proven rich sources widely used anticancer drugs, whereas some components human diet known act chemopreventive agents. present review explains role both categories inhibitors, viz., poisons, their in chemoprevention.

参考文章(84)
Giuseppe Di Lorenzo, Antonio Rea, Chiara Carlomagno, Stefano Pepe, Giovannella Palmieri, Roberto Labianca, Antonio Chirianni, Alfonso De Stefano, Vincenzo Esposito, Sabino De Placido, Vincenzo Montesarchio, Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study World Journal of Gastroenterology. ,vol. 13, pp. 6553- 6557 ,(2007) , 10.3748/WJG.V13.I48.6553
Yuk-Ching Tse, Karla Kirkegaard, James C Wang, Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. Journal of Biological Chemistry. ,vol. 255, pp. 5560- 5565 ,(1980) , 10.1016/S0021-9258(19)70666-8
R K Johnson, F H Drake, R D Woessner, C K Mirabelli, M R Mattern, Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth & Differentiation. ,vol. 2, pp. 209- 214 ,(1991)
John M. Fortune, Neil Osheroff, Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Progress in Nucleic Acid Research and Molecular Biology. ,vol. 64, pp. 221- 253 ,(2000) , 10.1016/S0079-6603(00)64006-0
Gregory A. Viglianti, Mary-Ann Bjornsti, James C. Wang, Piero Benedetti, Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Research. ,vol. 49, pp. 6318- 6323 ,(1989)
S Jensen, A H Andersen, E Kjeldsen, H Biersack, E H Olsen, T B Andersen, O Westergaard, B K Jakobsen, Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae. Molecular and Cellular Biology. ,vol. 16, pp. 3866- 3877 ,(1996) , 10.1128/MCB.16.7.3866
Adam C. Ketron, Neil Osheroff, Phytochemicals as anticancer and chemopreventive topoisomerase II poisons Phytochemistry Reviews. ,vol. 13, pp. 19- 35 ,(2014) , 10.1007/S11101-013-9291-7
Ling Wang, Shambhu K. Roy, David A. Eastmond, Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells Mutation Research. ,vol. 616, pp. 70- 82 ,(2007) , 10.1016/J.MRFMMM.2006.11.023
Ken Kobayashi, Mark J. Ratain, Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemotherapy and Pharmacology. ,vol. 34, ,(1994) , 10.1007/BF00684866